Skip to main content

Table 3 One-year follow-up univariate and multivariate survival analysis in FIGO stage III-IV for FOLR1 mRNA expression

From: Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers

    Univariatea Multivariateb
    PFS OS PFS OS
    Months (median) CI 95 % HR p value Months (median) CI 95 % HR p value HR CI 95 % p value HR CI 95 % p value
Type I FOLR1 mRNA expressionc Weak 8.56 7.06-10.06 0.246 [0.081-0.743] 0.006** 10.25 9.06-11.44 0.093 [0.012-0.717] 0.004** 0.38 0.16-0.87 0.023* 0.59 0.007-0.52 0.011*
  Strong 11.25 10.08-12.41 11.64 10.95-12.33
  Grading G1 VS G2-3          0.62 0.35-1.65 0.416 1.11 0.29-4.18 0.880
  Age < o > median          0.76 0.36-1.58 0.461 1.46 0.69-3.05 0.317
  Residual disease 0 VS >0          2.04 0.71-5.83 0.183 1.33 0.37-4.29 0.661
  histologyd           1.73 0.94-3.37 0.077 2.01 0.94-4.29 0.071
  FIGO stage I-II VS III-IV          2.08 0.84-5.11 0.110 1.01 0.30-3.83 0.982
Type II FOLR1 mRNA expressionc Weak 9.17 7.94-10.40 0.904 [0.577-1.414] 0.183 11.25 10.38-12.12 0.586 [0.170-2.023] 0.390       
  Strong 10.30 9.57-11.02 11.68 11.30-12.05       
  1. Cut off for FOLR1 mRNA expression = median value in the cancer cohort (9.14) *Significant at the 0.05 level, **Significant at the 0.01 level alog rank test, bCOX-regression analysis;
  2. cArbitrary units normalized to TBP. dSerous, endometrioid, mucinous and clear cell. Multivariate analysis was performed if p-value in univariate analysis was > 0.1